These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 28620891

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ, Chugh R.
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
    Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R, Cosaert J, Shahir A, Baggstrom MQ.
    Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
    [Abstract] [Full Text] [Related]

  • 25. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
    Seeber A, Weiss L, Romeder F, Szkandera J, Kuehr T, Kostner S, Pichler P, Jaeger T, Kocher F, Greil R, Brodowicz T.
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
    [Abstract] [Full Text] [Related]

  • 26. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
    Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL.
    Mol Cancer Ther; 2021 Jan; 20(1):132-141. PubMed ID: 33177152
    [Abstract] [Full Text] [Related]

  • 27. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
    Song EJ, Ashcraft KA, Lowery CD, Mowery YM, Luo L, Ma Y, Campos LDS, Cardona DM, Stancato L, Kirsch DG.
    EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
    [Abstract] [Full Text] [Related]

  • 28. Olaratumab: First Global Approval.
    Shirley M.
    Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
    Pender A, Jones RL.
    Clin Pharmacol; 2017 Jul; 9():159-164. PubMed ID: 29270033
    [Abstract] [Full Text] [Related]

  • 33. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
    Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.
    Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
    [Abstract] [Full Text] [Related]

  • 34. Olaratumab for soft tissue sarcoma.
    Teyssonneau D, Italiano A.
    Expert Opin Biol Ther; 2017 Aug; 17(8):1019-1025. PubMed ID: 28691538
    [Abstract] [Full Text] [Related]

  • 35. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
    Moroncini G, Maccaroni E, Fiordoliva I, Pellei C, Gabrielli A, Berardi R.
    Onco Targets Ther; 2018 Aug; 11():833-842. PubMed ID: 29497315
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F, Letrent SP, Sharma A.
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.